At the Forefront of Care
Retina Associates has a team of researchers that are focused on advancing and improving the treatment of diseases of the retina, macula and vitreous through clinical studies, teaching, and development of new instruments and techniques. Our physicians have participated in a multitude of research studies and in many our physicians have served as principal investigators or co-investigators.
Currently Enrolling
RGX-314 is being developed as a novel one-time gene therapy for the treatment of Neovascular Wet Age-Related Macular Degeneration as a potential one-time treatment for wet AMD.
RGX-314 is being developed as a novel one-time gene therapy for the treatment of Neovascular Wet Age-Related Macular Degeneration as a potential one-time treatment for wet AMD.
High Dose (8mg) Aflibercept for the treatment of Macular Edema secondary to Retina Vein Occlusion
Upcoming Studies:
A Study to Assess Safety and Efficacy of Multiple Doses of BI 771716 in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Home Guided Treatment verus Treat and Extend for the Management of Neovascular Age-Related Macular Degeneration